Chromosome aberrations and prognosis in preleukaemia

Area of Science:

• Hematology
• Cytogenetics
• Oncology

Background:

• Preleukaemia, also known as myelodysplastic syndromes, represents a group of clonal hematopoietic stem cell disorders.
• These disorders are characterized by ineffective hematopoiesis and a high risk of transformation into acute myeloid leukaemia.
• Cytogenetic abnormalities are common in preleukaemia and are associated with prognosis.

Purpose of the Study:

• To investigate the prognostic significance of cytogenetic findings in patients with preleukaemia.
• To correlate karyotype status with survival outcomes in a cohort of preleukaemia patients who progressed to acute non-lymphocytic leukaemia.

Main Methods:

• Cytogenetic analysis using G-banding staining technique was performed on 24 patients diagnosed with preleukaemia.
• Patients were categorized based on their karyotype findings: normal karyotype (NN), mixed normal and abnormal metaphases (AN), and abnormal metaphases only (AA).
• Survival time was analyzed and compared across the different karyotype groups.

Main Results:

• All 24 patients eventually developed acute non-lymphocytic leukaemia and died.
• Patients with a completely normal karyotype (NN-patients) had a median survival time of 8 months.
• Patients with both normal and abnormal metaphases (AN-patients) had a median survival time of 18.5 months.
• Patients with only abnormal metaphases (AA-patients) had the shortest median survival time of 3 months.

Conclusions:

• Cytogenetic status in preleukaemia is a critical prognostic factor.
• The presence and type of karyotypic abnormalities significantly influence survival duration.
• Patients with abnormal metaphases only (AA-patients) face a particularly poor prognosis, highlighting the need for early intervention and risk stratification.